Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom

References

• LalliSAlbaneseAThe diagnostic challenge of primarydystonia: evidence from misdiagnosisMov Disord201025111619162620629166
   PubMed Web of Science ®Google Scholar
• AlbaneseAAsmusFBhatiaKPEFNS guidelines on diagnosis and treatment of primary dystoniasEur J Neurol201118151820482602
   PubMed Web of Science ®Google Scholar
• BloudekLMStacyMSchwartzMBrinMPapapetropoulosSCost of cervical dystonia in the United States [abstract]Mov Disord2012154A142A413
   Google Scholar
• CoelhoMValadasAFMestreTFerreiraJJPain and quality of life in the treatment of cervical dystoniaEur Neurol Rev2009427478
   Google Scholar
• MarrasCVan den EedenSKFrossRDMinimum incidence of primary cervical dystonia in a multiethnic health care populationNeurology200769767668017698789
   PubMed Web of Science ®Google Scholar
• WarnerTCamfieldLMarsdenCA prevalence study of primary dystonia in eight European countriesJ Neurol20002471078779211127535
   PubMed Web of Science ®Google Scholar
• NuttJGMuenterMDAronsonAKurlandLTMeltonLJ3rdEpidemiology of focal and generalised dystonia in Rochester, MinnesotaMov Disord1988331881943264051
   PubMed Web of Science ®Google Scholar
• AbogunrinSBrandSDesaiKDinetJGabrielSHarrowerTAbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysisClinicoecon Outcomes Res2015744144926392782
   PubMedGoogle Scholar
• Dystonia - NHS Choices Available from: http://www.nhs.uk/conditions/dystonia/pages/introduction.aspxAccessed July 22, 2016
   Google Scholar
• ZoonsEDijkgraafMGDijkJMvan SchaikINTijssenMABotulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic valueJ Neurol2012259122519252622552527
   PubMed Web of Science ®Google Scholar
• WalkerFOBotulinum toxin therapy for cervical dystoniaPhys Med Rehabil Clin2003144749766
   Google Scholar
• SimpsonDavid MHallettMarkAshmanEric JPractice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headacheNeurology201686191818182627164716
   PubMed Web of Science ®Google Scholar
• HilkerRSchischniaschviliMGhaemiMJacobsARudolfJHealth related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystoniaJ Neurol Neurosurg Psychiatry200171219319911459891
   PubMed Web of Science ®Google Scholar
• SkogseidIMRøislienJClaussenBKertyELong-term botulinum toxin treatment increases employment rate in patients with cervical dystoniaMov Disord200520121604160916114026
   PubMed Web of Science ®Google Scholar
• MolhoESAgarwalNReganKHigginsDSFactorSAEffect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment statusMov Disord20092491384138719441129
   PubMed Web of Science ®Google Scholar
• ComellaCLJankovicJShannonKMTsuiJSwensonMLeurgansSFanWDystonia Study GroupComparison of botulinum toxin serotyopes A and B for the treatment of cervical dystoniaNeurology20056591423142916275831
   PubMed Web of Science ®Google Scholar
• ConskyEBasinskiABelleLRanawayaRLangAEThe Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability [abstract]Neurology199040Suppl 1445
   Google Scholar
• HanYStevensADashtipourKHauserRMariZA mixed treatment comparison (MTC) to compare the efficacy of botulinum toxin type A treatments for cervical dystoniaValue Health2014173A57
   Web of Science ®Google Scholar
• HanYStevensADashtipourKHauserRAMariZA mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystoniaJ Neurol2016263477278026914922
   PubMed Web of Science ®Google Scholar
• BrockmannKSchweitzerKBeckGWächterTComparison of different preparations of botulinumtoxin A in the treatment of cervical dystoniaNeurol Asia2012172115119
   Web of Science ®Google Scholar
• KazerooniRBroadheadCCost-utility analysis of botulinum toxin type A products for the treatment of cervical dystoniaAm J Health Syst Pharm201572430130725631837
   PubMed Web of Science ®Google Scholar
• SonnenbergFABeckJRMarkov models in medical decision making: a practical guideMed Decis Making19931343223388246705
   PubMed Web of Science ®Google Scholar
• BriggsASculpherMAn introduction to Markov modelling for economic evaluationPharmacoeconomics199813439740910178664
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)Guide to the methods of technology appraisal. 2013 NICE article [PMG9]LondonNICE Avaliable from: http://publication.nice.org.uk/pmg9Accessed January 2016
   Google Scholar
• TruongDBrodskyMLewMGlobal dysport cervical dystonia study groupLong-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystoniaParkinsonism Relat Disord201016531632320359934
   PubMed Web of Science ®Google Scholar
• Office for national statistics (ONS)Annual Survey of Hours and Earnings, 2013 Provisional Results2013 Available from: http://www.ons.gov.uk/ons/dcp171778_335027.pdfAccessed January 2016
   Google Scholar
• Electronic Medicines Compendium (eMC)Bortox® 100 units, Bortox® 50 units, Summary of Product Characteristics Available from: https://www.medicines.org.uk/emc/medicine/112; https://www.medicines.org.uk/emc/medicine/22562; https://www.medicines.org.uk/emc/medicine/20564Accessed January 2016
   Google Scholar
• Electronic medicines compendium (eMC)Dysport® 300 units, Dysport® 500 units, summary of product characteristics Available from: https://www.medicines.org.uk/emc/medicine/870Accessed January 2016
   Google Scholar
• Electronic medicines compendium (eMC)Xeomin® 100 units, Xeo-min® 50 units, summary of product characteristics Available from: https://www.medicines.org.uk/emc/medicine/20666; https://www.medicines.org.uk/emc/medicine/24582Accessed January 2016
   Google Scholar
• StacyMBloudekLSchwartzMBrinMPapapetropoulosSCervical dystonia substantially impacts employment status, absenteeism, and presenteeism: Baseline results from cervical dystonia patient registry for the observation of onabotulinumtoxinA efficacy (CD PROBE)Mov Disord2012271106
   Google Scholar
• TildenDGuarnieriCCost-Effectiveness of incobotulinumtoxin-A with flexible treatment intervals compared to onabotulinumtoxin-A in the management of blepharospasm and cervical dystoniaValue Health201619214515227021747
   PubMed Web of Science ®Google Scholar
• MartikainenKKLuukkaalaTHMarttilaRJWorking capacity and cervical dystoniaParkinsonism Relat Disord201016321521719660976
   PubMed Web of Science ®Google Scholar
• BurbaudPDucerfCCugyEBotulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness studyJ Neurol201125891670167521424611
   PubMed Web of Science ®Google Scholar
• BNF: joint formulary committeeBritish national formulary (online)2012 Available from: http://www.medicinescomplete.comAccessed December, 2012
   Google Scholar
• PSSUnit costs of health and social care 2011 and National Schedule of Reference Costs Year 2010–2011Personal social services research unit (PSS)2015 Available from: http://www.pssru.ac.ukAccessed January 2016
   Google Scholar
• KesslerKRSkuttaMBeneckeRLong-term treatment of cervical dys-tonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia study groupJ Neurol1999246426527410367694
   PubMed Web of Science ®Google Scholar